Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CV Therapeutics ranolazine

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Each of three dose levels of sustained-release ranolazine "was associated with statistically significant (p<0.005) increases in patients' treadmill exercise duration with no clinically meaningful effects on blood pressure or heart rate compared to placebo" in a pivotal trial, the company reported at the 49th annual meeting of the American College of Cardiology. The multicenter, double-blind MARISA (Monotherapy Assessment of Ranolazine In Stable Angina) study randomized 191 patients withdrawn from other anti-anginal drugs to 500 mg, 1000 mg, or 1500 mg ranolazine b.i.d. or placebo for a four-period study. Patients received each of the treatments for a seven-day period in a Latin square crossover design. Exercise testing with a modified Bruce protocol programmed into treadmills was performed at trough (12 hours after dosing) and peak (four hours after dosing). Results for 175 patients who completed three or four of the treatment periods showed exercise duration at trough of 559 seconds for the 1500 mg dose, 545 seconds for 1000 mg and 533 seconds for 500 mg vs. 511 seconds for placebo (p<0.001, p<0.001 and p=0.003, respectively). Time to angina at trough was 472 seconds (1500 mg), 457 seconds (1000 mg) and 437 mg (500 mg) vs. 412 seconds for placebo (p<0.001, p<0.001 and p=0.005). A second pivotal trial, CARISA, will test the drug in combination with other anti-angina agents. Results are expected next year

You may also be interested in...



Amwell Stock Rises 28% In Market Debut

Amwell’s increased the size of its IPO and raised $742m when it sold 41.2 million shares at $18 each.

Pink Sheet Podcast: COVID-19 Stresses Manufacturing, Vaccine Placebo Controls, Thorny FDA Precedents

Pink Sheet reporters and editor discuss the pandemic’s effects on non-coronavirus-related product manufacturing, US FDA efforts to ensure vaccine sponsors maintain placebo controls once a product is available, and precedents that burden the agency.

First EMA Nod For Generic Xarelto; Apotex Pulls Upkanz For Neurodegenerative Disease

While Accord HealthCare has convinced the European Medicines Agency that its rivaroxaban generic should be approved in the EU, Bayer has warned that patent protection for Xarelto continues until at least late 2023. The EMA this week also recommend approval for a number of other new drugs.

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel